



Change order details by crossing out unwanted information and writing in desired details/instructions.
Place a line through the x to remove the pre-checked option.

PEGLOTICASE (KRYSTEXXA) THERAPY PLAN [11500826] Columbia Network Infusion Centers

Select Location: Southwest/Vancouver St John/Longview Start Date: _____

Diagnosis/Indication: _____

ICD-10 Code(s): _____ Authorization Number: _____

Patient Vitals: Height _____ Weight _____

Provider Communication Orders

To reduce delays in treatment and phone calls to your office, you may participate in the PeaceHealth formulary process by selecting this option. A clinic pharmacist will adjust orders according to PeaceHealth site approved policies and procedures.

- I agree to utilize the PeaceHealth policies & procedures that have been reviewed by the Pharmacy & Therapeutics Committee and authorized by the Medical Executive Committee of PeaceHealth. This agreement will be issued for the duration of active orders contained within this treatment plan.

Labs

Interval

- Uric Acid Every 14 Days

Pre-Medications

Interval

- loratadine (CLARITIN) tablet 10 mg Every 14 Days Route: Oral
- acetaminophen (TYLENOL) tablet 650 mg Every 14 Days Route: Oral
- methylPREDNISolone sodium succinate (Solu-MEDROL) injection 40 mg Every 14 Days Route: IV
- Treatment Lab Instructions Every 14 Days
Release the following labs: Uric Acid, Serum. Provider approves to Release and Draw labs 2 days Pre & Post this planned treatment date.

Supportive Care

Interval

- PEGLOTICASE (KRYSTEXXA) IN 250 ML IVPB Route: IV
Dose 8 mg Frequency Every 14 Days

Nursing Orders

Interval

- Nursing Communication PRN
Consider discontinuing therapy if uric acid concentration rises above 6 mg/dL, particularly if 2 consecutive measurements exceed 6 mg/dL.
- Nursing Communication Every Visit
Monitor patient for hypersensitivity during infusion and 1 hour post infusion.

Vascular Access (single select)

Interval

- IV Every Visit
- Insert peripheral IV

Provider Signature

Date

Time

Provider's Printed Name: _____

Place Patient Label Here

Page 1 of 3

EHR5053-DT (09/12/2024)

PEGLOTICASE (KRYSTEXXA) THERAPY PLAN

- sodium chloride (NS) flush 10 mL
10 mL As Needed for Line Care
- Central line (non-PICC) Every Visit
 - Access vascular device and confirm patency
 - Initiate Central line (non-PICC) maintenance protocol
 - sodium chloride (NS) flush 10 mL
10 mL As Needed for Line Care prior to medication administration PRN
 - sodium chloride (NS) flush 10 mL
10 mL As Needed for Line Care post medication administration PRN
 - sodium chloride (NS) flush 20 mL
20 mL As Needed for Line Care post lab draw PRN
 - sodium chloride (NS) flush 10 mL
10 mL for Line Care at discharge and de-access every visit
 - heparin 100 units/mL 5 mL
5 mL for de-access every visit
 - alteplase (CATHFLO) injection 2 mg
Other, Starting when released, For 2 dose, For clearing central line catheter. Add 2.2 mL sterile water for injection to vial; let the vial stand undisturbed to allow large bubbles to dissipate. Mix gently swirling until completely dissolved (complete dissolution should occur within 3 minutes); do not shake. Final concentration: 1 mg/mL. Retain in catheter for 30 minutes to 2 hours, instill a 2nd dose if occluded
- PICC line Every Visit
 - Access vascular device and confirm patency
 - Initiate PICC maintenance protocol
 - Nursing Communication
Change PICC line dressing weekly and PRN
 - sodium chloride (NS) flush 10 mL
10 mL As Needed for Line Care prior to medication administration PRN
 - sodium chloride (NS) flush 10 mL
10 mL As Needed for Line Care post medication administration PRN
 - sodium chloride (NS) flush 20 mL
20 mL As Needed for Line Care post lab draw PRN
 - alteplase (CATHFLO) injection 2 mg
Other, Starting when released, For 2 dose, For clearing central line catheter. Add 2.2 mL sterile water for injection to vial; let the vial stand undisturbed to allow large bubbles to dissipate. Mix gently swirling until completely dissolved (complete dissolution should occur within 3 minutes); do not shake. Final concentration: 1 mg/mL. Retain in catheter for 30 minutes to 2 hours, instill a 2nd dose if occluded

PRN Medications	Interval	Route
○ sodium chloride (NS) flush 10 mL 10 mL As Needed for Line Care	PRN	Route: IV
○ sodium chloride 0.9 % bolus 500 mL 500 mL Once for Line Care, Starting when released, For 1 dose, Run at TKO (25ml/hr)	PRN	Route: IV

Emergency Medications	Interval	Route
X diphenhydrAMINE (BENADRYL) injection 25-50 mg 25-50 mg Once As Needed For mild to moderate drug reactions (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort, blood pressure changes (>= 20 points in SBP), nausea, urticaria, chills, pruritic). Administer 50 mg IV if patient has NOT had diphenhydramine within 2 hours of reaction. Administer 25 mg IV if patient has had diphenhydramine within 2 hours of reaction, if reaction doesn't resolve in 3 minutes may repeat 25 mg I dose for a total of 50 mg, and contact provider.	PRN	Route: IV

Provider Signature Date Time

Provider's Printed Name:

- X albuterol 90 mcg/actuation inhaler 2 puff PRN Route: Inhalation
2 puff Once As Needed Inhalation Wheezing, Shortness of Breath, wheezing, shortness of breath associated with infusion reaction and notify provider. Administer with a spacer if available.
- X methylPREDNISolone sodium succinate (Solu-MEDROL) Injection 125 mg PRN Route: IV
125 mg Once As Needed For shortness of breath for continued symptoms of mild to moderate drug reactions (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort, blood pressure changes (≥ 20 points in SBP), nausea, urticaria, chills, pruritic) that worsen or persist 5 minutes after administration of diphenhydramine (Benadryl), and contact provider.
- X EPINEPHrine (ADRENALIN) injection for Allergic Reaction 0.5 mg PRN Route: Intramuscular
0.5 mg Once As Needed For severe drug reaction (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort plus blood pressure changes (≥ 40 points in SBP), shortness of breath with wheezing and O2Sat $< 90\%$), and contact provider.

Provider Signature

Date

Time

Provider's Printed Name:

Place Patient Label Here

Page 3 of 3

EHR5053-DT (09/12/2024)

PEGLOTICASE (KRYSTEXXA) THERAPY PLAN